Clinical Trials Search
Clinical Trial 19185
Interventions:Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); OncoSil Microparticles / Diluent; gemcitabine
Study Type: Treatment
Phase of Study: NA
- Jason Klapman
An Open Label, Single Arm Pilot Study of OncoSil, Administered to Subjects with Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination with Gemcitabine or Gemcitabine+Nab-Paclitaxel Chemotherapies
The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil, when implanted into patients with pancreatic cancer, who are already receiving standard chemotherapy. OncoSil, is an experimental treatment. This means that it is not an approved treatment for pancreatic cancer anywhere in the world at this time.
To evaluate the safety of OncoSil. Primary Endpoint: Safety and Tolerability. Secondary Endpoints: Efficacy, Local Progression Free Survival (LPFS), within the pancreas, Progression Free Survival (PFS), all sites, Overall Survival (OS), Body weight, Impaired function, Pain Scores.